Literature DB >> 26690712

Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.

Manisha Bhutani1,2, Baris Turkbey3, Esther Tan1, Neha Korde1,4, Mary Kwok1, Elisabet E Manasanch1,5, Nishant Tageja1, Sham Mailankody1, Mark Roschewski1, Marcia Mulquin1, Ashley Carpenter1, Elizabeth Lamping1, Alex R Minter1, Brendan M Weiss1,6, Esther Mena3, Liza Lindenberg3, Katherine R Calvo7, Irina Maric7, Saad Z Usmani2, Peter L Choyke3, Karen Kurdziel3, Ola Landgren1,4.   

Abstract

The incidence and importance of bone marrow involvement and/or early bone lesions in multiple myeloma (MM) precursor diseases is largely unknown. This study prospectively compared the sensitivity of several imaging modalities in monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM) and MM. Thirty patients (10 each with MGUS, SMM and MM) were evaluated with skeletal survey, [18F]FDG-PET/CT, [18F]NaF-PET/CT and morphologic dynamic contrast enhanced (DCE)-MRI. An additional 16 SMM patients had skeletal surveys and FDG-PET/CT. Among MGUS patients, DCE-MRI found only one focal marrow abnormality; other evaluations were negative. Among 26 SMM patients, five (19%) were re-classified as MM based on lytic bone lesions on CT and six had unifocal or diffuse marrow abnormality. Among MM, marrow abnormalities were observed on FDG-PET/CT in 8/10 patients and on DCE-MRI in nine evaluable patients. Abnormal NaF uptake was observed only in MM patients with lytic lesions on CT, providing no additional clinical information.

Entities:  

Keywords:  DCE-MRI; FDG; MGUS; NaF; PET/CT; functional imaging; multiple myeloma; smoldering myeloma

Mesh:

Substances:

Year:  2016        PMID: 26690712      PMCID: PMC5576169          DOI: 10.3109/10428194.2015.1090572

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  18 in total

1.  Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?

Authors:  Daniel Spira; Katja Weisel; Harald Brodoefel; Maximilian Schulze; Sascha Kaufmann; Marius Horger
Journal:  Acad Radiol       Date:  2012-01       Impact factor: 3.173

2.  Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.

Authors:  Jens Hillengass; Kerstin Fechtner; Marc-André Weber; Tobias Bäuerle; Sofia Ayyaz; Christiane Heiss; Thomas Hielscher; Thomas M Moehler; Gerlinde Egerer; Kai Neben; Anthony D Ho; Hans-Ulrich Kauczor; Stefan Delorme; Hartmut Goldschmidt
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

3.  Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance.

Authors:  J Hillengass; M-A Weber; K Kilk; K Listl; B Wagner-Gund; M Hillengass; T Hielscher; A Farid; K Neben; S Delorme; O Landgren; H Goldschmidt
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

4.  Whole-body (18)F-FDG PET identifies high-risk myeloma.

Authors:  Brian G M Durie; Alan D Waxman; Allesandro D'Agnolo; Cindy M Williams
Journal:  J Nucl Med       Date:  2002-11       Impact factor: 10.057

5.  [Imaging in smoldering (asymptomatic) multiple myeloma. Past, present and future].

Authors:  M Bhutani; O Landgren
Journal:  Radiologe       Date:  2014-06       Impact factor: 0.635

Review 6.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

7.  Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

Authors:  Meletios A Dimopoulos; Jens Hillengass; Saad Usmani; Elena Zamagni; Suzanne Lentzsch; Faith E Davies; Noopur Raje; Orhan Sezer; Sonja Zweegman; Jatin Shah; Ashraf Badros; Kazuyuki Shimizu; Philippe Moreau; Chor-Sang Chim; Juan José Lahuerta; Jian Hou; Artur Jurczyszyn; Hartmut Goldschmidt; Pieter Sonneveld; Antonio Palumbo; Heinz Ludwig; Michele Cavo; Bart Barlogie; Kenneth Anderson; G David Roodman; S Vincent Rajkumar; Brian G M Durie; Evangelos Terpos
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

8.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

9.  Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial.

Authors:  M Bhutani; B Turkbey; E Tan; T J Kemp; L A Pinto; A R Berg; N Korde; A R Minter; B M Weiss; E Mena; L Lindenberg; O Aras; M P Purdue; J N Hofmann; S M Steinberg; K R Calvo; P L Choyke; I Maric; K Kurdziel; O Landgren
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

10.  Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT.

Authors:  Christopher J Hanrahan; Carl R Christensen; Julia R Crim
Journal:  Radiographics       Date:  2010-01       Impact factor: 5.333

View more
  9 in total

1.  Potential diagnostic role of diffusion tensor imaging in early-stage osteonecrosis of the femoral head.

Authors:  Hongwei Min; Feng Xu; Rui Gu; Xinzuo Han; Anqing Wang; Kemin Liu
Journal:  Exp Ther Med       Date:  2016-10-11       Impact factor: 2.447

2.  Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.

Authors:  Christos Sachpekidis; Jens Hillengass; Hartmut Goldschmidt; Hoda Anwar; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

3.  Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Christos Sachpekidis; J Hillengass; H Goldschmidt; B Wagner; U Haberkorn; K Kopka; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-29       Impact factor: 9.236

Review 4.  [Hemato-oncological imaging : Importance of hybrid procedures].

Authors:  M E Mayerhoefer; A Haug
Journal:  Radiologe       Date:  2016-07       Impact factor: 0.635

5.  11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions.

Authors:  Constantin Lapa; Maria J Garcia-Velloso; Katharina Lückerath; Samuel Samnick; Martin Schreder; Paula Rodriguez Otero; Jan-Stefan Schmid; Ken Herrmann; Stefan Knop; Andreas K Buck; Hermann Einsele; Jesus San-Miguel; Klaus Martin Kortüm
Journal:  Theranostics       Date:  2017-07-23       Impact factor: 11.556

6.  Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.

Authors:  Faith E Davies; Adam Rosenthal; Leo Rasche; Nathan M Petty; James E McDonald; James A Ntambi; Doug M Steward; Susan B Panozzo; Frits van Rhee; Maurizio Zangari; Carolina D Schinke; Sharmilan Thanendrarajan; Brian Walker; Niels Weinhold; Bart Barlogie; Antje Hoering; Gareth J Morgan
Journal:  Haematologica       Date:  2018-03-22       Impact factor: 9.941

7.  Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?

Authors:  Christos Sachpekidis; Annette Kopp-Schneider; Maximilian Merz; Anna Jauch; Marc-Steffen Raab; Hartmut Goldschmidt; Antonia Dimitrakopoulou-Strauss
Journal:  Cancers (Basel)       Date:  2020-05-23       Impact factor: 6.639

Review 8.  Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues.

Authors:  A Nervo; A Ragni; F Retta; M Gallo; A Piovesan; V Liberini; M Gatti; U Ricardi; D Deandreis; E Arvat
Journal:  J Endocrinol Invest       Date:  2020-08-03       Impact factor: 4.256

Review 9.  Immunological Prognostic Factors in Multiple Myeloma.

Authors:  Dominika Bębnowska; Rafał Hrynkiewicz; Ewelina Grywalska; Marcin Pasiarski; Barbara Sosnowska-Pasiarska; Iwona Smarz-Widelska; Stanisław Góźdź; Jacek Roliński; Paulina Niedźwiedzka-Rystwej
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.